Biden touts economic gains despite Americans’ poor opinions of job in officeNew reliever Jordan Romano ready to go ‘electric’ for PhilliesSome I'm A Celebrity fans think GK Barry and Ella Rutherford have secretly got married. Speculation was fuelled by Ipswich Town footballer Ella referring to GK as "my wife" on social media. The podcast star, whose real name is Grace Keeling, secured fifth place on this year's series of the ITV show. As GK, 25, made her exit, she was greeted by her sports star partner, 24, at the end of the bridge. Ella has now raised a few eyebrows with an Instagram post from her time in Australia, the Mirror reports. Alongside some images from Down Under, she wrote: "Flew to the jungle to get my wife. Met the most amazing people along the way and made memories that will last a life time. You made us all so proud beautiful, I love you with all my heart, I have everything I’ll ever need." READ MORE: I'm A Celeb's Coleen Rooney hints at exciting projects and says 'I'll be back really soon' Her comments wowed followers who rushed to the comments over the pair's romance. One fan wrote in the comments: "@ellarutherford_ got her wife Whata gem." Another wrote: "Love this Ella", followed by a heart and ring emoji. Those who weren't convinced the pair had yet wed had commented to encourage it. "Marry her already," wrote one. A second chimed in with: "I say put a ring on it." During her time in the jungle, GK was open about her relationship and said: “It was by accident I found Ella, through a mutual friend and then I really liked her the first day I met her, but I’d never told my parents. I’d mentioned, ‘Oh I’m just going to see my friend Ella’ or ‘I’m staying round Ella’s’ so they’d heard her name.” She told her fellow campmates her parents had later visited while Ella and asked who she was. Recounting the story, GK said: "I told them 'Oh. she’s my girlfriend'. They just love her, they never had an issue with it. To be fair I feel like the closet may have been glass!” When she was voted off the series, GK vowed never to walk away from her girlfriend again. She said: "Never again, are we leaving each other. We must be joined at the hip at all times. She basically said to me, 'this is your moment.....this is all about you'. I feel like it says a lot about her."
MINNEAPOLIS — A Connecticut couple has been charged in Minnesota with being part of a shoplifting ring suspected of stealing around $1 million in goods across the country from the upscale athletic wear retailer Lululemon. Jadion Anthony Richards, 44, and Akwele Nickeisha Lawes-Richards, 45, both of Danbury, Connecticut, were charged this month with one felony count of organized retail theft. Both went free last week after posting bail bonds of $100,000 for him and $30,000 for her, court records show. They're due back in Ramsey County District Court in St. Paul on Dec. 16. According to the criminal complaints, a Lululemon investigator had been tracking the pair even before police first confronted them on Nov. 14 at a store in suburban Roseville. The investigator told police the couple were responsible for hundreds of thousands of dollars in losses across the country, the complaints said. They would steal items and make fraudulent returns, it said. Police found suitcases containing more than $50,000 worth of Lululemon clothing when they searched the couple's hotel room in Bloomington, the complaint said. According to the investigator, they were also suspected in thefts from Lululemon stores in Colorado, Utah, New York and Connecticut, the complaint said. Within Minnesota, they were also accused of thefts at stores in Minneapolis and the suburbs of Woodbury, Edina and Minnetonka. Get the latest breaking news as it happens. By clicking Sign up, you agree to our privacy policy . The investigator said the two were part of a group that would usually travel to a city and hit Lululemon stores there for two days, return to the East Coast to exchange the items without receipts for new items, take back the new items with the return receipts for credit card refunds, then head back out to commit more thefts, the complaint said. In at least some of the thefts, it said, Richards would enter the store first and buy one or two cheap items. He'd then return to the sales floor where, with help from Lawes-Richards, they would remove a security sensor from another item and put it on one of the items he had just purchased. Lawes-Richards and another woman would then conceal leggings under their clothing. They would then leave together. When the security sensors at the door went off, he would offer staff the bag with the items he had bought, while the women would keep walking out, fooling the staff into thinking it was his sensor that had set off the alarm, the complaint said. Richards' attorney declined comment. Lawes-Richards' public defender did not immediately return a call seeking comment Monday. “This outcome continues to underscore our ongoing collaboration with law enforcement and our investments in advanced technology, team training and investigative capabilities to combat retail crime and hold offenders accountable,” Tristen Shields, Lululemon's vice president of asset protection, said in a statement. "We remain dedicated to continuing these efforts to address and prevent this industrywide issue.” The two are being prosecuted under a state law enacted last year that seeks to crack down on organized retail theft. One of its chief authors, Sen. Ron Latz, of St. Louis Park, said 34 states already had organized retail crime laws on their books. “I am glad to see it is working as intended to bring down criminal operations," Latz said in a statement. "This type of theft harms retailers in myriad ways, including lost economic activity, job loss, and threats to worker safety when crime goes unaddressed. It also harms consumers through rising costs and compromised products being resold online.” Two Minnesota women were also charged under the new law in August. They were accused of targeting a Lululemon store in Minneapolis.
Rupert Murdoch's audacious bid to cement his eldest son's control over one of the world's most influential media empires has failed, a US report said Monday. The first family of news -- commanding a stable that includes Fox News, The Wall Street Journal and a host of British and Australian media -- had been the inspiration for the hit TV series "Succession." Like the fictional version, this real-life fight pitted the children of a powerful patriarch against each other for who should be the face and the voice of the empire after the old man dies. Murdoch, now 93, had long intended that his children inherit the empire, and jointly decide its direction. The eldest daughter, Prudence, has had little involvement in the family business, but at various times the other three -- Lachlan, James and Elisabeth -- have all been considered as successors. But in recent years Murdoch senior had reportedly grown concerned that Fox News -- the crown jewels of the collection -- might drift away from its lucrative right-wing moorings after his death, to reflect the more centrist views of James and Elisabeth. He had therefore sought to designate Lachlan -- who currently heads Fox News and News Corp -- as the controlling player in the wider business. That had required rewriting the terms of an irrevocable trust that passed power to the four siblings jointly, stripping three of them of voting power, while allowing them to continue to benefit financially. Rupert Murdoch had argued that giving control to Lachlan -- who is understood to share his father's worldview -- was in the financial interests of the whole brood. The family intrigue played out behind closed doors in a Nevada courtroom, where Murdoch senior and his four children were understood to have given several days' evidence in September. In a decision filed at the weekend, probate commissioner Edmund J. Gorman Jr. said the father and son had acted in "bad faith" in trying to rewrite the rules, The New York Times reported, citing a copy of the sealed court document. The plan to alter the trust's structure was a "carefully crafted charade" to "permanently cement Lachlan Murdoch's executive roles." "The effort was an attempt to stack the deck in Lachlan Murdoch's favor after Rupert Murdoch's passing so that his succession would be immutable," the Times cited the ruling as saying. "The play might have worked; but an evidentiary hearing, like a showdown in a game of poker, is where gamesmanship collides with the facts and at its conclusion, all the bluffs are called and the cards lie face up. "The court, after considering the facts of this case in the light of the law, sees the cards for what they are and concludes this raw deal will not, over the signature of this probate commissioner, prevail." Murdoch's lawyer, Adam Streisand, did not immediately reply to an AFP request for comment. The ruling is not final, and must now be ratified or rejected by a district judge. That ruling could be challenged, perhaps provoking another round of legal arguments. The complicated structure of the irrevocable trust reflects the colourful familial relationships that shaped Rupert Murdoch's life as he built the multibillion-dollar empire. The trust was reported to have been the result of a deal agreed with his second wife -- mother of Lachlan, Elisabeth and James -- who wanted to ensure her offspring would not be disenfranchised by children Murdoch had with his third wife, Wendi Deng. The Murdoch empire has transformed tabloid newspapers, cable TV and satellite broadcasting over the last few decades while facing accusations of stoking populism across the English-speaking world. Brexit in Britain and the rise of Donald Trump in the United States are credited at least partly to Murdoch and his outlets. hg/nroTrump taps forceful ally of hard-line immigration policies to head Customs and Border Protection
Final Jeopardy Today December 6, 2024 – Question, Answer, Wages & WinnerFrom a 10-year-old to a Muppet to a president-elect, NYSE bell-ringers range from famous to obscure
Legacy of S M Krishna: A Tribute to a Statesman
Trump taps forceful ally of hard-line immigration policies to head Customs and Border Protection
Vikings staying on track and in control behind Sam Darnold's composure and confidence
This retired autoworker has been greeting people at local Walmart for 17 years — and now on TikTokTesla Stock Falls As Analyst Says 'Animal Spirits' Spur Post-Election Rally, Not FundamentalsNoneTHOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE Amgen
By REBECCA SANTANA, Associated Press WASHINGTON (AP) — The picture of who will be in charge of executing President-elect Donald Trump’s hard-line immigration and border policies has come into sharper focus after he announced his picks to head Customs and Border Protection and also the agency tasked with deporting immigrants in the country illegally. Trump said late Thursday he was tapping Rodney Scott, a former Border Patrol chief who’s been a vocal supporter of tougher enforcement measures, for CBP commissioner. As acting director of Immigration and Customs Enforcement, Trump said he’d nominate Caleb Vitello, a career ICE official with more than 23 years in the agency who most recently has been the assistant director for firearms and tactical programs. They will work with an immigration leadership team that includes South Dakota Gov. Kristi Noem as head of the Department of Homeland Security ; former acting Immigration and Customs Enforcement head Tom Homan as border czar ; and immigration hard-liner Stephen Miller as deputy chief of staff. Customs and Border Protection, with its roughly 60,000 employees, falls under the Department of Homeland Security. It includes the Border Patrol, which Scott led during Trump’s first term, and is essentially responsible for protecting the country’s borders while facilitating trade and travel. Scott comes to the job firmly from the Border Patrol side of the house. He became an agent in 1992 and spent much of his career in San Diego. When he joined the agency, San Diego was by far the busiest corridor for illegal crossings. Traffic plummeted after the government dramatically increased enforcement there, but critics note the effort pushed people to remote parts of California and Arizona. San Diego was also where wall construction began in the 1990s, which shaped Scott’s belief that barriers work. He was named San Diego sector chief in 2017. When he was appointed head of the border agency in January 2020, he enthusiastically embraced Trump’s policies. “He’s well known. He does know these issues and obviously is trusted by the administration,” said Gil Kerlikowske, the CBP commissioner under the Obama administration. Kerlikowske took issue with some of Scott’s past actions, including his refusal to fall in line with a Biden administration directive to stop using terms like “illegal alien” in favor of descriptions like “migrant,” and his decision as San Diego sector chief to fire tear gas into Mexico to disperse protesters. “You don’t launch projectiles into a foreign country,” Kerlikowske said. At the time Scott defended the agents’ decisions , saying they were being assaulted by “a hail of rocks.” While much of the focus of Trump’s administration may be on illegal immigration and security along the U.S.-Mexico border, Kerlikowske also stressed the importance of other parts of Customs and Border Protection’s mission. The agency is responsible for securing trade and international travel at airports, ports and land crossings around the country. Whoever runs the agency has to make sure that billions of dollars worth of trade and millions of passengers move swiftly and safely into and out of the country. And if Trump makes good on promises to ratchet up tariffs on Mexico, China and Canada, CBP will play an integral role in enforcing them. “There’s a huge amount of other responsibility on trade, on tourism, on cyber that take a significant amount of time and have a huge impact on the economy if it’s not done right,” Kerlikowske said. After being forced out under the Biden administration, Scott has been a vocal supporter of Trump’s hard-line immigration agenda. He has appeared frequently on Fox News and testified in Congress. He’s also a senior fellow at the Texas Public Policy Foundation. In a 2023 interview with The Associated Press, he advocated for a return to Trump-era immigration policies and more pressure on Mexico to enforce immigration on its side of the border.
Weave Communications stock hits 52-week high at $14.52Matt Gaetz says he won't return to Congress next year after withdrawing name for attorney general WASHINGTON (AP) — Matt Gaetz is not coming back to Congress. The Florida Republican said Friday he has no intention of serving another term in the House now that he is no longer President-elect Donald Trump's nominee for attorney general. Gaetz withdrew as the nominee this week amid growing fallout from the allegations of sexual conduct against him. Gaetz denies the allegations. Gaetz didn't lay out his plans now that he's out of office, saying only, “I’m still going to be in the fight, but it’s going to be from a new perch." After Gaetz's withdrawal on Thursday, Trump named former Florida attorney general Pam Bondi to lead the Justice Department. Vance takes on a more visible transition role as he works to boost Trump's most controversial picks WASHINGTON (AP) — After several weeks working behind closed doors, Vice President-elect JD Vance returned to Capitol Hill this week in a new, more visible role. He's been helping Donald Trump’s most contentious Cabinet picks try to win confirmation in the Senate, where he has served for the last two years. Vance spent part of Wednesday at the Capitol with Rep. Matt Gaetz sitting in on meetings with Trump’s controversial choice for attorney general. On Thursday, Vance was back, this time accompanying Pete Hegseth. Vance is expected to accompany other nominees for meetings over the coming weeks as he tries to leverage the two years he has spent in the Senate to help push through Trump’s picks. Beyond evangelicals, Trump and his allies courted smaller faith groups, from the Amish to Chabad Donald Trump’s lock on the white evangelical vote is legendary, but he didn't focus exclusively on large religious voter blocs. He and his allies also wooed smaller religious groups, away from the mainstream. He posted a tribute to Coptic church members on social media and met with members of Assyrians for Trump — two smaller Christian communities with Middle Eastern roots. He visited the grave of the revered late leader of an Orthodox Jewish movement. His allies sought votes from the separatist Amish community. While Trump won decisively, the outreaches reflected aggressive campaigning in what was expected to be a tight race. NATO and Ukraine to hold emergency talks after Russia's attack with new hypersonic missile KYIV, Ukraine (AP) — NATO and Ukraine will hold emergency talks Tuesday after Russia attacked a central city with a hypersonic ballistic missile that escalated the nearly 33-month-old war. Ukraine's parliament canceled a session Friday over the security threat. In a stark warning to the West, President Vladimir Putin said in a nationally televised speech Thursday that the attack with the intermediate-range Oreshnik missile was retaliation for Kyiv’s use of U.S. and British longer-range missiles capable of striking deeper into Russian territory. Putin said Russia is launching production of the Oreshnik, saying it's so powerful that several of them fitted with conventional warheads could be as devastating as a strike with strategic — or nuclear — weapons. Texas education board approves optional Bible-infused curriculum for elementary schools AUSTIN, Texas (AP) — Texas’ education board has voted to allow Bible-infused teachings in elementary schools. The approval Friday follows other Republican-led states that have pushed this year to give religion a larger presence in public classrooms. The curriculum adopted by the Texas State Board of Education is optional for schools to adopt, but they’ll receive additional funding if they do so. Parents and teachers who opposed the curriculum say the lessons will alienate students of other faith backgrounds. Supporters argue the Bible is a core feature of American history and that teaching it will enrich learning. 2 convicted in human smuggling case after Indian family froze to death on US-Canada border FERGUS FALLS, Minn. (AP) — A jury has convicted two men of charges related to human smuggling for their roles in an international operation that led to the deaths of a family of Indian migrants who froze while trying to cross the Canada-U.S. border during a 2022 blizzard. Harshkumar Ramanlal Patel and Steve Shand each faced four charges related to human smuggling before being convicted on Friday. Patel is an Indian national. Shand is an American from Florida. They were arrested after the family froze while trying to cross the desolate border during a 2022 blizzard. Northern California gets record rain and heavy snow. Many have been in the dark for days in Seattle FORESTVILLE, Calif. (AP) — A major storm with heavy snow and record rain that's moving through Northern California has toppled trees, closed roads and prompted evacuations in some areas after knocking out power to hundreds of thousands of people in Washington and Oregon. Forecasters warn that the risk of flash flooding and rockslides will continue through Friday. The National Weather Service has extended a flood watch for areas north of San Francisco as a plume of moisture known as an atmospheric river inundates Northern California and the Pacific Northwest. Up to 16 inches of rain is forecast in Northern California and southwestern Oregon. The storm system unleashed winds earlier this week that left two people dead and hundreds of thousands without power in Washington. Archaeologists discover 4,000-year-old canals used to fish by predecessors of ancient Maya WASHINGTON (AP) — Using drones and Google Earth imagery, archaeologists have discovered a 4,000-year-old network of earthen canals in what’s now Belize. The research published Friday in Science Advances shows that long before the ancient Maya built temples, their predecessors were already altering the landscape of Central America’s Yucatan peninsula. The ancient fish canals were used to channel and catch freshwater species such as catfish. These structures were used for around 1,000 years — including during the “formative” period when the Maya began to settle in permanent farming villages and a distinctive culture started to emerge. California case is the first confirmed bird flu infection in a US child Health officials are confirming bird flu in a California child — the first reported case in a U.S. minor. The Centers for Disease Control and Prevention announced confirmatory test results on Friday. Officials say the child had mild symptoms, was treated with antiviral medication and is recovering. The child’s infection brings the reported number of U.S. bird flu cases this year to 55, including 29 in California. State officials have said the child lives in Alameda County, which includes Oakland, and attends day care, but released no other details. Giants release quarterback Daniel Jones just days after benching him EAST RUTHERFORD, N.J. (AP) — The Daniel Jones era in New York is over. The Giants quarterback was granted his release by the team just days after the franchise said it was benching him in favor of third-stringer Tommy DeVito. New York president John Mara said Jones approached the team about releasing him and the club obliged. Mara added he was “disappointed” at the quick dissolution of a once-promising relationship between Jones and the team. Giants coach Brian Daboll benched Jones in favor of DeVito following a loss to the Panthers in Germany that dropped New York's record to 2-8.Notre Dame puts losing streak in past, turns focus to Dartmouth
THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE Amgen
Daniel Ricciardo receives ‘whatever it takes’ offer to block F1 return route – reportAnti-Labour election petition boosted by 'fascist cranks', say Greens
